Nadia Omelchenko, MD, Sarcoma Oncology Research Center, Santa Monica, CA, summarizes the current landscape for predictive biomarkers for checkpoint inhibitors (CI) in sarcoma. Expression of PD-(L)1 and CTLA-4 has been explored as biomarkers to predict response to CI treatment in various cancers, though there is no trial data yet for advanced sarcomas. Sarcoma cells are greatly immunogenic, but the Phase II SAINT study (NCT03138161) shows promising progress free survival and overall survival through the use of trabectedin, ipilimumab and nivolumab. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
